HIVconsvX Vaccine Description
HIVconsvX vaccine candidate will induce the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV – an “Achilles heel” common to most HIV variants.
This vaccine is a “mosaic” that can target a range of HIV-1 variants, opening up the possibility that this single drug could be used across the globe.
The phase 1 trial is part of the European Aids Vaccine Initiative (EAVI2020), an international collaborative research project funded by the European Commission under the Horizon 2020 health program for research and innovation.
The Jenner Institute Laboratories at the Old Road Campus in Headington, Oxford, has been supported by the University of Oxford, the Jenner Vaccine Foundation, the Medical Research Council, and the Wolfson Foundation.
HIVconsvX Vaccine Indication
HIVconsvX Vaccine candidate strategy is to help both HIV-negative individuals for prevention and in people living with HIV for a cure. An estimated 36.7 million people are chronically infected with Human Immunodeficiency Virus (HIV), the virus that, if untreated, causes AIDS. Vaccination is the most effective way to prevent many infectious diseases, but developing effective vaccines against HIV is extremely challenging. One of the main reasons for this is the extraordinary ability of the virus to change its genes.
HIVconsvX Vaccine News
July 5, 2021 - HIV vaccine trial starts at Oxford University in England. Preclinical studies have been performed in small animals without safety concerns. ChAdOx1.tHIVconsv1 is a first in human vaccine. The MVA.tHIVconsvX vaccines used in this study have been given to a small number of people in the USA. Professor Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute, University of Oxford, and lead researcher of the trial, said: ‘An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for a cure.’
June 11, 2021 - Original Article: Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.
July 6, 2020 - Study: Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth.
HIVconsvX Vaccine Clinical Trial
The University of Oxford today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK. The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region. Thirteen healthy, HIV-negative adults aged 18-65 and who are considered not to be at high risk of infection will initially receive one dose of the vaccine followed by a further booster dose at four weeks. The trial is part of the European Aids Vaccine Initiative (EAVI2020). The researchers hope to be able to report the results of the HIV-CORE 0052 trial by April 2022.
During this study, 3 volunteers will be vaccinated in group 1, and 10 volunteers will be vaccinated in group 2. Group 1 will receive one vaccine (ChAdOx1.tHIVconsv1) and have a total of 6 visits over 4 months. Group 2 volunteers will receive three vaccines (ChAdOx1.tHIVconsv1 alone and MVA.tHIVconsv3 and MVA.tHIVconsv4 given in combination one month later) and have a total of 11 visits over 5 months.